bluebird bio, Inc.·4

Jun 12, 4:31 PM ET

Walsh Jeffrey T. 4

4 · bluebird bio, Inc. · Filed Jun 12, 2019

Insider Transaction Report

Form 4
Period: 2019-06-10
Walsh Jeffrey T.
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    2019-06-10$126.96/sh200$25,39240,921 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-06-101,40010,121 total
    Exercise: $24.47Exp: 2024-03-03Common Stock (1,400 underlying)
  • Exercise/Conversion

    Common Stock

    2019-06-10$24.47/sh+1,400$34,25842,321 total
  • Sale

    Common Stock

    2019-06-10$125.19/sh1,200$150,22741,121 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
  • [F2]The range of prices for the transaction reported on this line was $125.00 to $125.55. The average weighted price was $125.1892. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION